Emergent BioSolutions, Inc. (EBS)
5.89
-0.15
(-2.48%)
USD |
NYSE |
Nov 12, 16:00
5.885
0.00 (0.00%)
Pre-Market: 20:00
Emergent BioSolutions Free Cash Flow (Quarterly) : 96.80M for Sept. 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 96.80M |
| June 30, 2026 | 54.00M |
| March 31, 2026 | -36.20M |
| December 31, 2025 | 73.80M |
| September 30, 2025 | -5.70M |
| June 30, 2025 | 103.50M |
| March 31, 2025 | -14.80M |
| December 31, 2024 | -81.60M |
| September 30, 2024 | 147.90M |
| June 30, 2024 | 42.90M |
| March 31, 2024 | -73.40M |
| December 31, 2023 | 20.70M |
| September 30, 2023 | 47.40M |
| June 30, 2023 | -126.90M |
| March 31, 2023 | -199.10M |
| December 31, 2022 | 69.20M |
| September 30, 2022 | -345.60M |
| June 30, 2022 | -47.70M |
| March 31, 2022 | -69.50M |
| December 31, 2021 | 282.30M |
| September 30, 2021 | -38.50M |
| June 30, 2021 | -96.70M |
| March 31, 2021 | -51.00M |
| December 31, 2020 | 209.10M |
| September 30, 2020 | 59.50M |
| Date | Value |
|---|---|
| June 30, 2020 | 92.80M |
| March 31, 2020 | 33.60M |
| December 31, 2019 | 86.00M |
| September 30, 2019 | -18.40M |
| June 30, 2019 | -49.90M |
| March 31, 2019 | 83.40M |
| December 31, 2018 | -186.59M |
| September 30, 2018 | 147.92M |
| June 30, 2018 | 20.98M |
| March 31, 2018 | -12.61M |
| December 31, 2017 | 66.50M |
| September 30, 2017 | 20.74M |
| June 30, 2017 | 44.70M |
| March 31, 2017 | 21.37M |
| December 31, 2016 | -29.19M |
| September 30, 2016 | -15.40M |
| June 30, 2016 | -2.144M |
| March 31, 2016 | 23.96M |
| December 31, 2015 | -8.111M |
| September 30, 2015 | 90.81M |
| June 30, 2015 | -8.096M |
| March 31, 2015 | -74.96M |
| December 31, 2014 | 35.77M |
| September 30, 2014 | 73.70M |
| June 30, 2014 | 6.009M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 545.80M |
| Arcturus Therapeutics Holdings, Inc. | -6.114M |
| Capricor Therapeutics, Inc. | -40.21M |
| Travere Therapeutics, Inc. | 69.45M |
| Syndax Pharmaceuticals, Inc. | -27.25M |